FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894150647> ?p ?o ?g. }

• W2894150647 endingPage "e12707" @default.
• W2894150647 startingPage "e12707" @default.
• W2894150647 abstract "Topical minoxidil is an effective, FDA-approved treatment for androgenetic alopecia (AGA) (Dinh & Sinclair, 2007) and has also been shown to help traction alopecia (TA) (Khumalo & Ngwanya, 2007). However, some patients may find its use inconvenient or costly. Orally, minoxidil is prescribed as an antihypertensive with potential cardiac side-effects such as edema, pericarditis, or pericardial effusion (Weber et al., 2014). Approximately 80% of its users develop hypertrichosis with elongation and thickening of hair at various sites including the scalp (Pfizer Canada, 2013). However, potential cardiovascular effects may discourage its prescription for hair loss by dermatologists. This case series details the tolerability and adherence rates of oral minoxidil for treatment of AGA or TA. Using the electronic medical records (EMR; YES EMR, Toronto, Canada) of two dermatology clinics, patients with AGA or TA who were prescribed oral minoxidil from December 2016 through January 2018 were identified. These patients were diagnosed clinically by the author (RAB). They had previously used topical minoxidil and were seeking alternate treatment. Accordingly, they were prescribed oral minoxidil 1.25 mg nightly. This dose was determined in 2016 after reviewing reports of successful hair growth with 1 mg dosing (Sinclair, 2016; Yang & Thai, 2015), and based on the availability of a 2.5 mg tablet in Canada, which was halved. All patients were informed about the drug's indication and side-effect profile (Pfizer Canada, 2013). Patients with prior hypotension, cardiac comorbidities, or lack of prescription contraception were not prescribed the medication. Clinic notes were assessed for prescription compliance, reports of side-effects, and other unique details. All patients prescribed minoxidil, regardless of their adherence to the prescription, were included in this as-treated analysis. The search identified a total of 20 patients (18 women and two men, average age 41 years old) who were prescribed oral minoxidil (Table 1). Patients with a primary diagnosis of AGA (16 patients; 80%) or TA (four patients; 20%) were prescribed an initial 3-month course. Eighteen out of 20 patients filled their prescription for oral minoxidil (90%); two were discouraged by prescription warnings. The medication was continued by 14/18 (78%) patients at reassessment. Patients who discontinued oral minoxidil cited aversion to pills (2), forgetfulness (1), and headache with stress of a new job (1). The average duration of prescription use across all 18 patients was 6 months. Blood pressure monitoring was requested of all patients. Among 9 patients who monitored their blood pressure, it either remained within normal range (7 patients) or improved from hypertensive levels (two patients). One patient (6%) reported hypotensive symptoms and urticaria for 8–10 days. No patients experienced significant cardiac morbidity. Six of 18 patients (33%) reported decreased hair shedding, while five patients (28%) reported increased scalp hair (5/18). Hypertrichosis was reported in 39% (7/18) on the face (most commonly the skin lip) and arms, yet all affected patients continued therapy due to its perceived benefit for their scalp hair. Aside from tolerability, there are 5 practical advantages of this therapy—the 5 C's of oral minoxidil. It may be more convenient to swallow minoxidil than to apply it topically, especially for patients who do not wet their hair daily. Patients noted enhanced cosmesis, because prescription oral therapy did not distort gray hair color or generate product residue. At $37 CDN (USD $28.60) for a 3 months' supply, oral minoxidil offered cost-savings relative to the topical over-the-counter product. Co-therapy such as application of commercial keratin fibers to visually enhance fullness was simpler without use of competing topical minoxidil on the scalp. Finally, 78% of patients continued oral therapy at last follow-up, thus demonstrating good compliance. With other recent reports indicating therapeutic benefit of oral minoxidil (Perera & Sinclair, 2017), subsequent investigations that objectively measure scalp hair growth and help establish optimal dosing of oral minoxidil should be considered. none. none." @default.
• W2894150647 created "2018-10-05" @default.
• W2894150647 creator A5036931038 @default.
• W2894150647 date "2018-09-24" @default.
• W2894150647 modified "2023-10-03" @default.
• W2894150647 title "Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability & the five C's of oral therapy" @default.
• W2894150647 cites W1503506954 @default.
• W2894150647 cites W1668023273 @default.
• W2894150647 cites W2008071024 @default.
• W2894150647 cites W2396515819 @default.
• W2894150647 cites W2586133222 @default.
• W2894150647 cites W2752289241 @default.
• W2894150647 doi "https://doi.org/10.1111/dth.12707" @default.
• W2894150647 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6586015" @default.
• W2894150647 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30246901" @default.
• W2894150647 hasPublicationYear "2018" @default.
• W2894150647 type Work @default.
• W2894150647 sameAs 2894150647 @default.
• W2894150647 citedByCount "41" @default.
• W2894150647 countsByYear W28941506472019 @default.
• W2894150647 countsByYear W28941506472020 @default.
• W2894150647 countsByYear W28941506472021 @default.
• W2894150647 countsByYear W28941506472022 @default.
• W2894150647 countsByYear W28941506472023 @default.
• W2894150647 crossrefType "journal-article" @default.
• W2894150647 hasAuthorship W2894150647A5036931038 @default.
• W2894150647 hasBestOaLocation W28941506471 @default.
• W2894150647 hasConcept C126322002 @default.
• W2894150647 hasConcept C128057223 @default.
• W2894150647 hasConcept C16005928 @default.
• W2894150647 hasConcept C197934379 @default.
• W2894150647 hasConcept C2426938 @default.
• W2894150647 hasConcept C2775876775 @default.
• W2894150647 hasConcept C2776028589 @default.
• W2894150647 hasConcept C2776360568 @default.
• W2894150647 hasConcept C2777288759 @default.
• W2894150647 hasConcept C2778375690 @default.
• W2894150647 hasConcept C2779711729 @default.
• W2894150647 hasConcept C2911091166 @default.
• W2894150647 hasConcept C71924100 @default.
• W2894150647 hasConcept C98274493 @default.
• W2894150647 hasConceptScore W2894150647C126322002 @default.
• W2894150647 hasConceptScore W2894150647C128057223 @default.
• W2894150647 hasConceptScore W2894150647C16005928 @default.
• W2894150647 hasConceptScore W2894150647C197934379 @default.
• W2894150647 hasConceptScore W2894150647C2426938 @default.
• W2894150647 hasConceptScore W2894150647C2775876775 @default.
• W2894150647 hasConceptScore W2894150647C2776028589 @default.
• W2894150647 hasConceptScore W2894150647C2776360568 @default.
• W2894150647 hasConceptScore W2894150647C2777288759 @default.
• W2894150647 hasConceptScore W2894150647C2778375690 @default.
• W2894150647 hasConceptScore W2894150647C2779711729 @default.
• W2894150647 hasConceptScore W2894150647C2911091166 @default.
• W2894150647 hasConceptScore W2894150647C71924100 @default.
• W2894150647 hasConceptScore W2894150647C98274493 @default.
• W2894150647 hasIssue "6" @default.
• W2894150647 hasLocation W28941506471 @default.
• W2894150647 hasLocation W28941506472 @default.
• W2894150647 hasLocation W28941506473 @default.
• W2894150647 hasLocation W28941506474 @default.
• W2894150647 hasOpenAccess W2894150647 @default.
• W2894150647 hasPrimaryLocation W28941506471 @default.
• W2894150647 hasRelatedWork W2094185878 @default.
• W2894150647 hasRelatedWork W2302251733 @default.
• W2894150647 hasRelatedWork W2894150647 @default.
• W2894150647 hasRelatedWork W2899175872 @default.
• W2894150647 hasRelatedWork W2968810751 @default.
• W2894150647 hasRelatedWork W3047153462 @default.
• W2894150647 hasRelatedWork W3118393645 @default.
• W2894150647 hasRelatedWork W3194061732 @default.
• W2894150647 hasRelatedWork W4291368533 @default.
• W2894150647 hasRelatedWork W4297463318 @default.
• W2894150647 hasVolume "31" @default.
• W2894150647 isParatext "false" @default.
• W2894150647 isRetracted "false" @default.
• W2894150647 magId "2894150647" @default.
• W2894150647 workType "article" @default.